GlassScriptPhysician profile
Rafique Ahmed
NPI 1457354854
$3,742.77
in general payments reported to CMS, 2019-2025
19 companies · $98.98 in 2025
The $98.98 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,202 · 2020: $1,895 · 2021: $249 · 2022: $21.58 · 2023: $205 · 2024: $71.30 · 2025: $98.98.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $375.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,912.40 | 2019-2020 | |
| Genentech, INC. | $686.07 | 2019 | |
| Abbott Laboratories | $231.62 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $216.18 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $125.00 | 2019 | |
| Impulse Dynamics (USA) INC. | $84.82 | 2023 | Optimizer |
| Amgen INC. | $76.60 | 2023-2024 | Repatha |
| Boston Scientific Corporation | $63.43 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $48.67 | 2025 | |
| Medtronic Vascular, INC. | $47.78 | 2020 | |
| Kiniksa Pharmaceuticals International, Plc | $36.82 | 2024 | Arcalyst |
| Ge Healthcare | $35.08 | 2019 | |
| Kestra Medical Technology Services, INC. | $32.58 | 2023 | Assure Wcd |
| E.R. Squibb & Sons, L.L.C. | $30.44 | 2023 | Eliquis |
| Medtronic, INC. | $28.63 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $28.49 | 2025 | Opsynvi |
| Scpharmaceuticals INC. | $21.82 | 2025 | |
| Biotronik INC. | $21.58 | 2022 | |
| Esperion Therapeutics, INC. | $14.76 | 2024 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rafique Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.